COMPUGEN LTD (CGEN) 1.01 +0.03 (+3.45%)
1.01 +0.03 (+3.45%)
IL0010852080 - Common Stock
Why Shares of Compugen Jumped 17.86% on Thursday
The company is receiving a $7.5 milestone payment from AstraZeneca for the use of one of its therapies.
Why Compugen Stock Crumbled Today
Investors indicated their displeasure with the company's recent fundamentals.
Compugen Reports Third Quarter 2022 Results
New encouraging preliminary clinical data, presented at SITC 2022, showing anti-tumor activity supported by potent immune activation in the tumor...
Compugen to Participate in the Stifel Healthcare Conference
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today...
Compugen Announces Receipt of Nasdaq Delisting Notice
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today...
Why Shares of Compugen Jumped 9.27% on Tuesday
The stock's rise came after the company announced when third-quarter earnings will be presented.
Compugen to Release Third Quarter 2022 Results on Monday, November 14, 2022
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today...
Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today...
Compugen Announces Appointment of Alberto Sessa as Chief Financial Officer
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today...
5 Top Stocks Cathie Wood Sold This Week
August was not a pleasant month for Cathie Wood and ARKK as the ETF experienced outflows of $803 million, the most since last September.
Compugen Expands anti-PVRIG COM701 Patent Portfolio with New Composition of Matter and Use Patent in Japan
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today...
Compugen Expands anti-PVRIG COM701 Intellectual Property Portfolio
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today...
Compugen Reports Second Quarter 2022 Results
Prioritized two indications, MSS-CRC and NSCLC, utilizing fully owned assets, COM701 and COM902 Focus on MSS-CRC and NSCLC expected to provide highest...
Compugen to Release Second Quarter Results on Thursday, August 4, 2022
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today...
Compugen to Present at Upcoming Industry Conferences
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced...